[go: up one dir, main page]

SA520411635B1 - A2a مشتق حلقي مدمج كمثبط مستقبل - Google Patents

A2a مشتق حلقي مدمج كمثبط مستقبل

Info

Publication number
SA520411635B1
SA520411635B1 SA520411635A SA520411635A SA520411635B1 SA 520411635 B1 SA520411635 B1 SA 520411635B1 SA 520411635 A SA520411635 A SA 520411635A SA 520411635 A SA520411635 A SA 520411635A SA 520411635 B1 SA520411635 B1 SA 520411635B1
Authority
SA
Saudi Arabia
Prior art keywords
fused ring
receptor inhibitor
ring derivative
receptor
compound
Prior art date
Application number
SA520411635A
Other languages
English (en)
Inventor
هو بويو
شين شوهوي
زهو كاي
اكس شين كيفين
زياو مينليانج
Original Assignee
سـستوني فارماسيوتيكالـز (سوزهو) كو.، ليمتد
سـستوني فارماسيوتيكالـز (شانجهاي) كو.، ليمتد
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by سـستوني فارماسيوتيكالـز (سوزهو) كو.، ليمتد, سـستوني فارماسيوتيكالـز (شانجهاي) كو.، ليمتد filed Critical سـستوني فارماسيوتيكالـز (سوزهو) كو.، ليمتد
Publication of SA520411635B1 publication Critical patent/SA520411635B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

يتعلق الاختراع الحالي بمركب ممثل بالصيغة (1) أو ملح منه مقبول صيدلانيًا، وتطبيق المركب compound أو الملح slat في تحضير عقاقير دوائية drugs لعلاج أمراض diseases متعلقة بمستقبل receptor A2A .
SA520411635A 2017-09-28 2020-03-27 A2a مشتق حلقي مدمج كمثبط مستقبل SA520411635B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201710900542 2017-09-28
CN201810239824 2018-03-21

Publications (1)

Publication Number Publication Date
SA520411635B1 true SA520411635B1 (ar) 2022-05-24

Family

ID=65900821

Family Applications (1)

Application Number Title Priority Date Filing Date
SA520411635A SA520411635B1 (ar) 2017-09-28 2020-03-27 A2a مشتق حلقي مدمج كمثبط مستقبل

Country Status (15)

Country Link
US (1) US11312715B2 (ar)
EP (1) EP3686199B9 (ar)
JP (1) JP6836693B2 (ar)
KR (1) KR102254660B1 (ar)
CN (1) CN111542520B (ar)
AU (1) AU2018341781B2 (ar)
CA (1) CA3077267C (ar)
ES (1) ES2927086T3 (ar)
IL (1) IL273606B (ar)
MX (1) MX383975B (ar)
RU (1) RU2748993C1 (ar)
SA (1) SA520411635B1 (ar)
SG (1) SG11202002886PA (ar)
TW (1) TWI788424B (ar)
WO (1) WO2019062803A1 (ar)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110655509B (zh) * 2018-06-29 2023-01-24 江苏恒瑞医药股份有限公司 2-胺基嘧啶类衍生物、其制备方法及其在医药上的应用
CN111094254B (zh) * 2018-07-12 2022-07-26 江苏恒瑞医药股份有限公司 杂芳基类衍生物、其制备方法及其在医药上的应用
CN111377873B (zh) * 2018-12-28 2023-03-28 四川科伦博泰生物医药股份有限公司 氨基嘧啶化合物及其制备方法和用途
EP3950694B1 (en) * 2019-03-28 2024-07-17 Cstone Pharmaceuticals (Suzhou) Co., Ltd. Salt form and crystal form of a2a receptor antagonist and preparation method therefor
CN118955502A (zh) * 2020-07-23 2024-11-15 上海赛岚生物科技有限公司 一类具有激酶抑制活性的化合物
CN116514803A (zh) * 2022-01-21 2023-08-01 上海赛岚生物科技有限公司 一种激酶抑制剂的盐晶型和自由碱晶型

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT821682E (pt) 1995-04-21 2000-11-30 Meiji Seika Kaisha Compostos de benzimidazola e sua utilizacao enquanto moduladores do complexo de receptores gaba a?
JP4195729B2 (ja) * 1997-03-24 2008-12-10 協和醗酵工業株式会社 ［１，２，４］トリアゾロ［１，５−ｃ］ピリミジン誘導体
PT1303272E (pt) * 2000-06-21 2008-04-14 Hoffmann La Roche Derivados de benzotiazole
EP1308441B1 (en) 2000-08-11 2009-10-07 Eisai R&D Management Co., Ltd. 2-aminopyridine compounds and use thereof as drugs
DK1737831T3 (da) * 2004-04-02 2013-08-19 Prana Biotechnology Ltd Neurologisk aktive forbindelser
ES2241496B1 (es) 2004-04-15 2006-12-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridina.
ES2274712B1 (es) * 2005-10-06 2008-03-01 Laboratorios Almirall S.A. Nuevos derivados imidazopiridina.
EP1903044A1 (en) 2006-09-14 2008-03-26 Novartis AG Adenosine Derivatives as A2A Receptor Agonists
ES2542555T3 (es) * 2009-03-20 2015-08-06 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Derivados oxidados de triazolilpurinas útiles como ligandos del receptor A2A de adenosina y su uso como medicamentos
DE102012019369A1 (de) 2012-10-02 2014-04-03 Merck Patent Gmbh 7-Azaindolderivat
WO2014101120A1 (en) * 2012-12-28 2014-07-03 Merck Sharp & Dohme Corp. Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
CN105025899B (zh) 2012-12-28 2017-08-18 默沙东公司 具有A2A拮抗剂性质的杂二环取代的‑[1,2,4]三唑并[1,5‑c]喹唑啉‑5‑胺化合物
RU2534804C1 (ru) 2013-08-05 2014-12-10 Общество С Ограниченной Ответственностью "Ньювак" (Ооо "Ньювак") ЗАМЕЩЕННЫЕ [1,2,4]ТРИАЗОЛО[4,3-a]ПИРИДИНЫ, ПРОЯВЛЯЮЩИЕ СВОЙСТВА АНТАГОНИСТОВ АДЕНОЗИНОВЫХ А2А РЕЦЕПТОРОВ, И ИХ ПРИМЕНЕНИЕ
JP6275410B2 (ja) 2013-08-06 2018-02-07 大和ハウス工業株式会社 固定具
WO2015027431A1 (en) 2013-08-29 2015-03-05 Merck Sharp & Dohme Corp. 2,2-difluorodioxolo a2a receptor antagonists
AU2018244935A1 (en) * 2017-03-30 2019-08-15 F. Hoffmann-La Roche Ag Naphthyridines as inhibitors of HPK1

Also Published As

Publication number Publication date
TWI788424B (zh) 2023-01-01
MX2020003732A (es) 2021-06-29
JP2020535196A (ja) 2020-12-03
CA3077267C (en) 2021-02-16
MX383975B (es) 2025-03-14
ES2927086T3 (es) 2022-11-02
AU2018341781A1 (en) 2020-04-30
EP3686199A4 (en) 2021-04-07
TW201920171A (zh) 2019-06-01
WO2019062803A1 (zh) 2019-04-04
KR20200055126A (ko) 2020-05-20
AU2018341781A8 (en) 2020-05-07
IL273606A (en) 2020-05-31
BR112020006185A2 (pt) 2020-10-13
US20200239465A1 (en) 2020-07-30
EP3686199B9 (en) 2022-12-07
IL273606B (en) 2021-05-31
RU2748993C1 (ru) 2021-06-02
KR102254660B1 (ko) 2021-05-24
CA3077267A1 (en) 2019-04-04
EP3686199A1 (en) 2020-07-29
EP3686199B1 (en) 2022-08-03
JP6836693B2 (ja) 2021-03-03
SG11202002886PA (en) 2020-04-29
US11312715B2 (en) 2022-04-26
AU2018341781B2 (en) 2023-03-30
CN111542520A (zh) 2020-08-14
CN111542520B (zh) 2022-04-15

Similar Documents

Publication Publication Date Title
SA520411635B1 (ar) A2a مشتق حلقي مدمج كمثبط مستقبل
PH12019501688A1 (en) Pyridine derivative as ask1 inhibitor and preparation method and use thereof
MY196292A (en) Steroid Derivative Fxr Agonist
NZ764613A (en) Macrocyclic compound serving as wee1 inhibitor and applications thereof
EP4071149A3 (en) Heterocyclic compounds and uses thereof
EA033544B1 (ru) Производные пиридона в качестве ингибиторов киназы, реаранжированной во время трансфекции (ret)
SG10201811384TA (en) Mnk inhibitors and methods related thereto
TW201613593A (en) Molecules for administration to ROS1 mutant cancer cells
CY1124251T1 (el) Παραγωγα καρβοξαμιδιου
MY181641A (en) Amino pyran ring derivative and composition and use thereof
PH12019501955A1 (en) Tri-cycle compound and applications thereof
MX2020010618A (es) Derivados de pirazolotriazolopiriminina como antagonista del receptor a2a.
MX2016014946A (es) Derivados de carboxamida.
MX2017009292A (es) Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3.
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
MX379576B (es) Derivados de azetidina
WO2016006975A3 (en) Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof
WO2016006974A3 (en) Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof
MX2018015990A (es) Compuestos terapeuticos.
JOP20200127A1 (ar) مشتقات بيريدينون واستخدامها كمثبطات alk-2 انتقائية
MY180727A (en) Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzeimer?s disease
EA038580B9 (ru) Агонист fxr, представляющий собой производное стероидов
PH12016502247A1 (en) Carboxamide derivatives